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Acute antibody-mediated rejection is an unsolved issue in
transplantation, especially in the context of pretransplant
immunization. The deleterious effect of preformed cytotoxic
anti-HLA antibodies through complement activation is well
proven, but very little is known concerning complement
blockade to prevent/cure this rejection. Here, we used a
baboon model of preimmunization to explore the prevention
of acute antibody-mediated rejection by an early inhibition of
the classical complement pathway using human recombinant
C1-inhibitor. Baboons were immunized against peripheral
blood mononuclear cells from allogeneic donors and, once a
specific and stable immunization had been established, they
received a kidney from the same donor. Rejection occurred at
day 2 posttransplant in untreated presensitized recipients,
with characteristic histological lesions and complement
deposition. As recombinant human C1-inhibitor blocks
in vitro cytotoxicity induced by donor-specific antibodies,
other alloimmunized baboons received the drug thrice
daily intravenously during the first 5 days after transplant.
Rejection was prevented during this treatment but occurred
after discontinuation of treatment. We show here that early
blockade of complement activation by recombinant human
C1-inhibitor can prevent acute antibody-mediated rejection
in presensitized recipients. This treatment could also be
useful in other forms of acute antibody-mediated rejection
caused by induced antibodies.
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Acute antibody (Ab)-mediated rejection (AAMR) remains a
major hurdle in transplantation, with a constant incidence
(8–10% in renal transplantation) and a markedly poor
prognosis (27–40% of graft loss at 1 year).1,2 The diagnosis
of AAMR in renal allograft is based on three well-defined
cardinal features:1 (1) morphological evidence of acute tissue
injury; (2) immunopathological evidence of Ab involvement
(C4d and/or immunoglobulin (Ig) deposition3); and (3) sero-
logical evidence of circulating Abs to donor antigens (Ags).
Preformed donor-specific Abs (DSAs), induced by earlier
blood transfusions, transplantations, or pregnancies, have a
central role in this physiopathology. DSA are strongly
associated with kidney graft loss and related to an increased
risk of AAMR.4,5
Multiple forms of aggressive therapies are used to treat or
prevent AAMR (reviewed in Gloor et al.6), such as high-dose
intravenous (i.v.) Ig, immunoadsorption/plasmapheresis, and
anti-lymphocyte Abs. However, the efficacy of these treat-
ments is questionable, given the elevated percentage of graft
loss at 1 year and the high rate of severe, refractory, and
steroid-resistant AAMR. More recently, the addition of
rituximab (anti-CD20 monoclonal Ab) with or without
desensitization protocols led to an improvement in outcome
in patients suffering from AAMR,7 although refractory
rejections still occurred, probably mediated by spleen
memory B cells and bone marrow plasma cells that do not
express CD20. Some groups have suggested adding splenect-
omy as a rescue therapy, which would eliminate the majority
of the lymphocyte pool and possibly some plasma cells.8 All
of these desensitization procedures aim at lowering DSA
levels and their activity or at depleting DSA-secreting cells.
However, besides high-dose i.v. Ig that has an inhibitory
effect on complement activation in vitro,9 none of these
desensitization procedures target the classical complement
pathway activated by Ag–Ab binding.
The role of the classical complement pathway is broadly
documented in allo- and xenotransplantation.10 Briefly, the
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classical pathway is activated on C1q binding to Ab–Ag
complexes, leading to the formation of split products such as
C4d, and finally to the deposition of membrane attack
complex C5b–9, cell lysis, and severe graft injury. Several
strategies that inhibit complement activation at different
steps have been reported, such as the use of the soluble
complement receptor 1,11 C5a receptor antagonist,12
anti-C5a Ab,13 and cobra venom factor,14 in the ABO-
incompatible or xenotransplantation settings. Transgenic
expression of human complement regulatory molecules, such
as CD46,15 CD55, and CD59,16 has also shown efficacy in pig
xenografts. A few studies reported the use of concentrated
C1-inhibitor (a physiological inhibitor) extracted from
human plasma, to specifically block the classical pathway
by acting directly at its first step of activation.17,18 Recently, a
recombinant human C1-inhibitor (rhC1INH) has been
developed, produced in transgenic rabbit milk,19 and is
currently undergoing phase III clinical trials for the treatment
of hereditary angioedema.20 We have recently proven that
this rhC1INH inhibits in vitro cytotoxicity induced by
allo- and xenoantibodies.21
The aim of this study was to analyze the effect of this
rhC1INH (provided by Pharming technologies BV, Leiden,
The Netherlands) in the prevention of AAMR in presensi-
tized baboon renal allograft recipients. Here, we describe a
model of AAMR in nonhuman primates, and show that early
blockade of the classical complement pathway alone, by
rhC1INH, is sufficient and effective at preventing acute
AAMR during the treatment phase.
RESULTS
Alloimmunization
Two intradermal injections of donor peripheral blood
mononuclear cells (PBMCs), with a 2-week interval, were
sufficient to immunize all baboons. As determined by
fluorescence-activated cell sorting (FACS), anti-donor IgG
Abs were detectable in recipient sera 2 weeks after the second
injection and increased until reaching a plateau after 3–4
weeks (Figure 1a). Some animals (3 of 10 in this study)
developed earlier alloAbs (at 2 weeks after the first injection)
and were therefore immunized a second time in order for the
transplantations to be performed systematically during the
plateau phase at a similar time after immunization. These
alloAbs were specifically directed against donor Ag, as they
bound donor cells, but neither autologous nor third-party
cells (Figure 1b). The second peak of fluorescence detected by
FACS corresponded to a nonspecific binding of the secondary
Ab on B-cell membrane Ig. Recipient sera were then tested
for cytotoxicity against donor cells at day 0 and at the plateau
phase of the alloimmunization. Specific cytotoxicity for
donor cells was observed without cytotoxicity against the
third-party cells (Figure 1c). Finally, donor-specific sera lost
their cytotoxicity when preabsorbed on donor platelets
(expressing only class I Ag; Figure 1d), proving that the
induced alloAbs were cytotoxic and directed against donor
major histocompatibility complex class I molecules.
rhC1INH inhibits alloAb-mediated cytotoxicity
The efficiency of rhC1INH in inhibiting complement
activation by alloAb was analyzed by a cytotoxicity assay.
Recipient sera were tested for cytotoxicity against donor cells
at the alloimmunization plateau, with increasing concentra-
tions of rhC1INH. Cytotoxicity was inhibited by rhC1INH in
a dose-dependent manner and was totally abolished at 2 g/l
(Figure 1e).
Anti-donor presensitization induces AAMR
Whereas nonimmunized and nonimmunosuppressed ba-
boons (n¼ 3) rejected their kidney allograft around day 6
posttransplantation, preimmunized recipients (n¼ 4) devel-
oped an accelerated rejection (P¼ 0.0134): three animals
rejected at day 2 and one at day 3 (Figure 2a–d). At autopsy,
none of the animals showed any signs of disseminated
intravascular coagulation, platelet consumption, or vascular
thrombosis (data not shown). Graft histology after rejection
in nonimmunized animals showed typical signs of acute
cellular rejection, with a large and diffuse mononuclear cell
infiltrate with tubulitis and some vascular infiltration
(Figure 3). In contrast, presensitized recipient grafts showed
severe alterations and lesions characteristic of AAMR, with
interstitial hemorrhage, edema, a diffuse acute tubular
necrosis, intraglomerular thrombosis, fibrinoid necrosis,
capillary margination of inflammatory cells, and also a small
mononuclear cell infiltrate, but no tubulitis or intimal
arteritis (Figure 3). By immunohistochemistry, deposition
of C5b–9 and C3c was detected around glomeruli and
tubules, as well as in arteries and capillaries, but was absent in
controls. However, whereas C3c staining clearly revealed
peritubular capillaries, C4d staining remained essentially
restricted to glomeruli and arteriolar endothelium (Figure 3).
Finally, the dense CD3þ and CD20þ cell infiltrates present
in rejected grafts of nonsensitized recipients were barely
detectable in rejected grafts of alloimmunized monkeys
(Figure 3). IgG staining was poor (data not shown), but
Abs can be broken down or internalized.
rhC1INH therapy prevents AAMR in presensitized recipients
Preliminary experiments showed the estimated half-life of
rhC1INH to beB6 h (data not shown). Therefore, recipients
received i.v. injection every 8 h during the first 5 post-
transplant days. The two first alloimmunized baboons,
receiving 100 U/kg of rhC1INH, showed suboptimal plasma
concentrations, with a Cmax at 15 min rising to just 0.6 g/l
(Figure 4a). One of these two recipients rejected on day 4,
whereas the second one rejected on day 6, 1 day after
treatment discontinuation (Figure 2a–d). The four subse-
quent recipients received 200 U/kg and showed a better
pharmacological profile, with a Cmax of 1 g/l at 15 min,
but with the same C0 as recipients receiving 100 U/kg
(Figure 4a). No rejection occurred during the treatment,
but did so rapidly thereafter at days 6 and 7, similar to the
nonsensitized untreated recipients, except for one animal,
which rejected later at day 14 after transplantation
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(Figure 2a–d). As expected, total IgG sera levels decreased in
both groups (Figure 4b), suggesting an early but not
deleterious, without complement activation, Ab binding into
the graft. However, serum monitoring of the C3 and C4
complement fractions (Figure 4c and d), as well as analysis of
the classical (50% complement hemolysis, CH50), alternate
(50% alternate pathway, AP50), and mannose-binding lectin
(50% mannose-binding lectin pathway, MBL50) pathways of
the complement system (Figure 4e–i) did not differ
significantly between treated and nontreated animals. On
the other hand, a functional kinetic study of CH50, covering
the half-life of the rhC1INH, on two treated animals showed
that complement classical pathway was inhibited as long as
rhC1INH was circulating in the periphery (Figure 4f).
Finally, some activation of the alternate pathway was noticed
from day 1 in all groups, probably due to the surgical stress as
already known.20 Histological examination of the rejected
organs at 1 week after drug discontinuation in the treated
group showed characteristic signs of AAMR and also of acute
cellular rejection (Figure 3). Complement deposition did not
differ at rejection between untreated presensitized recipients
and recipients treated with 100 U/kg (data not shown), but
C4d artery staining was absent, and C3c as well as C5b–9
deposition were much less pronounced in the 200 U/kg
group, even 1–2 days after drug discontinuation (Figure 3).
More importantly, kidney biopsies performed under
treatment (200 U/kg) at day 3 after transplantation showed any
of the specific C4d, C3c, or C5b–9 deposition, as well as a poor
T-cell and B-cell infiltration (Figure 3), showing that during
the effective phase treatment, complement classical pathway
activation was efficiently inhibited locally inside the graft.
DISCUSSION
The increasing detection of AAMR in allotransplantation
together with the suboptimal current treatments justify the
need to develop a relevant preclinical model to study the
mechanisms involved in this pathology and to test new
therapeutic strategies. In this study, we describe a stringent
primate model of rapid AAMR that could look close to
hyperacute rejection described in presensitized patients,
ABO-incompatible transplantation, and xenotransplantation.
Moreover, we show that early blockade of the classical
complement pathway through rhC1INH is effective at
preventing this form of rejection.
According to our previous study in pigs,22 two subsequent
intradermal injections of donor PBMCs were sufficient to
immunize all recipients before transplantation. To ensure a
stringent and reproducible model of AAMR, we preferred not
to perform transplantation before the appearance of alloAbs,
but rather only in graft recipients with a positive cross-
match, with a plateau of anti-donor alloAbs. All immunized
animals developed specific anti-donor Abs directed against
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Figure 1 | Specificity and cytotoxicity of the induced alloantibody (alloAb). (a) Kinetics of anti-donor immunoglobulin G (IgG)
development after primary immunization analyzed by fluorescence-activated cell sorting (FACS) each week. (b) Appearance of specific IgG,
measured by FACS, against donor but not third-party or autologous cells in immunized animals at day 28 after primary immunization in
comparison with day 0. (c) Complement-mediated cytotoxicity of immunized recipient serum against donor (n¼ 6) but not third-party cells
(n¼ 3) at the plateau of immunization. (d) Depletion of anti-donor class I Abs in immunized recipient sera by donor platelet absorption
abolished cytotoxicity, proving the induced alloAb to be specific for donor major histocompatability complex class I (n¼ 6). (e) Anti-donor
alloAb cytotoxicity is inhibited by increased recombinant human C1-inhibitor (rhC1INH) concentration (n¼ 3).
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major histocompatibility complex Class I molecules that were
cytotoxic in the presence of complement. This sensitization
procedure resulted in an accelerated rejection of the im-
munizing donor organ, within 48–72 h, as opposed to 1 week
for untreated nonimmunized baboons. At transplantectomy,
rejected kidneys were characterized by an intense edema,
congestion, hemorrhagic infiltration, or even graft ruptures
without obvious signs of disseminated intravascular coagula-
tion. The histology of these rejected grafts was compatible
with that observed in presensitized or hyperimmunized
patients with severe humoral injury. Infiltrating cells were
rare at day 2, and were therefore unlikely to contribute to the
rejection processes, to any great extent. C4d staining outside
PTC (peritubular capillaries) (glomeruli, vessels etc.) in
humans is generally considered as nonspecific. In this model,
complement deposition (C3c, C4d, and C5b–9) was restricted
to the mesangium, tubules, and blood vessels. Only C3c
staining was detected in PTC. C4d, the well-characterized
molecule that stains PTC in humans, thus appears to be less
specific in nonhuman primates.
Given the pivotal role of complement-fixing alloAb clearly
described in this context of AAMR, the aim of this study was
to test the effect of blocking classical complement pathway
activation, with a view of associating this strategy with other
anti-humoral therapies. Recently, Montgomery’s group
successfully used an Ab (Eculizumab) directed against the
complement protein C5 to treat severe AAMR.23 rhC1INH is
currently being studied in a phase III trial of hereditary
angioedema, but to date has never been used in transplanta-
tion or autoimmunity. This molecule may offer the
advantage of specifically blocking the classical activation
pathway and leaving the alternative and lectin pathways
intact so as to preserve antibacterial defense. As previously
described,21 this molecule was very efficient in vitro at
inhibiting induced alloAb cytotoxicity. The 6–8 h half-life of
rhC1INH in baboons meant that we had to establish a
protocol of three i.v. injections per day. Such a treatment
schedule could only be envisioned in the context of a short-
term treatment of a rejection crisis or during the induction
phase. In this proof of concept study, we administrated the
drug for 5 days simply to test whether monotherapy using
complement blockade would enable the preimmunized
recipients to experience the same posttransplant course as
nonimmunized recipients who reject after days 5–6. The
plasma concentrations of C1-inhibitor reached in our model
seemed to be efficient in preventing AAMR during the
effective treatment phase. As expected, most of our treated
animals rejected their grafts at day 6 or 7, with humoral
rejection and a few signs of cellular injury. However, early
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Figure 2 |Clinical and biological effects of recombinant human C1-inhibitor (rhC1INH) administration in presensitized transplanted
recipients. (a) Renal allograft survival in nonimmunized baboons (n¼ 3), immunized baboons without therapy (n¼ 4), in those treated with
100U/kg of rhC1INH (n¼ 2), or those with 200U/kg of rhC1INH (n¼ 4). *P¼ 0.0134 versus the nonimmunized group. **P¼ 0.0058 versus the
nontreated immunized group. (b) Daily diuresis of immunized baboons without therapy (n¼ 4), treated with 100U/kg of rhC1INH (n¼ 2) or
200U/kg of rhC1INH (n¼ 4). (c) Daily creatinine levels and (d) blood urea nitrogen measurement after transplantation in immunized
recipients without therapy (n¼ 4), in those treated with 100U/kg of rhC1INH (n¼ 2) or in those treated with 200U/kg of rhC1INH (n¼ 4).
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nontreated immunized animals, showed a very efficient
inhibition of complement deposition within the graft under
treatment. It is clear that a full curative strategy should
associate T-cell and B-cell immunosuppression. This will be
the object of our next in vivo studies in this model. In
immunized, untreated, rejected animals, no activation of the
classical pathway was noticed in peripheral blood, but was
observed only locally inside grafts. On the other hand, we
observed during the rhC1INH use that, as long as the
molecule was circulating, classical pathway complement
activation was efficiently inhibited in the serum. However,
once the drug was no longer circulating, complement activity
returned to normal, suggesting that, according to the half-life
of the molecule, a continuous perfusion could be considered
for future experiments or clinical trials. C1-inhibitor has also
been described as having a broad range of effects of potential
interest in the context of transplantation, such as inhibition
of T-cell activation, inhibition of leukocyte transmigration,
inhibition of endothelial activation, and protection against
ischemia–reperfusion damage (reviewed in Davis et al.24). We
therefore hypothesized that this broad range of additional
effects could explain this late rejection at 14 days after
transplantation, without any additional treatment, in one




















Figure 3 |Analysis of kidney allograft histology. Histology (hematoxylin and eosin staining) and immunostaining of infiltrating cells
(CD3 and CD20) and complement deposition (C5b-9, C4d, and C3c) in kidney biopsies or grafts explanted from untreated nonimmunized
recipients, untreated immunized recipients, and recombinant human C1-inhibitor (rhC1INH) (200U/kg)-treated immunized recipients
at early phase (days 2–3) or later point (1 week).
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not observe any reduction in T-cell infiltration in other
recipients and no effect was observed in vitro in T-cell
activation and proliferation assays (data not shown). One
important risk of any complement inhibiting strategy,
especially in the context of additional immunosuppression,
is a potentially increased susceptibility to infection. An
interesting characteristic of C1-inhibitor is its protective role
in sepsis through enhancement of bacterial uptake by and/or
bactericidal capacity of phagocytes.25 Moreover, we could
anticipate as well its use in Ab-mediated renal diseases such
as lupus nephropathy or vascularitis.
In conclusion, we describe here a stringent preclinical model
of AAMR in nonhuman primates that enabled us to study the
mechanisms involved in the pathogenesis and to test a new
strategy aimed at preventing or treating AAMR. In this study,
we showed that early blockade of the classical complement
pathway alone, using the rhC1INH molecule, could prevent
AAMR in presensitized and hyperimmunized baboons. These
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Figure 4 |Complement monitoring. (a) C1 inhibitor levels in immunized transplant recipients treated with recombinant human
C1-inhibitor (rhC1INH) at 100U/kg (n¼ 2; dashed line) or 200U/kg (n¼ 2; solid line). (b) Total immunoglobulin G, (c) C3, and (d) C4 plasma
level measurement after transplantation in immunized recipients without therapy (n¼ 4; dotted line) or in those treated with rhC1INH
(n¼ 4; solid line). (e) The 50% complement hemolysis (CH50) analyzed by enzyme-linked immunosorbent assay, (f) Functional CH50 kinetics
analyzed during the first few hours after transplantation by sheep erythrocyte assay on two immunized recipients treated with 200U/kg of
rhC1INH, (g) the 50% alternate pathway (AP50), (h) the 50% mannose-binding lectin pathway (MBL 50) and (i) MBL plasma level measurement
after transplantation in immunized recipients without therapy (n¼ 4; dotted line) or in those treated with 100U/kg of rhC1INH (n¼ 2; solid line).
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data suggest that this molecule may be even more efficient in
less severe experimental or clinical situations. More studies will
be required to assess whether the association of C1INH-based
complement inhibition with other strategies aimed at lowering
DSA levels, and/or eliminating secreting and memory B cells,
could improve the overall impact on AAMR.
MATERIALS AND METHODS
Animals
In vivo studies were performed on 13 baboons (Papio anubis; from
the CNRS primatology center, Rousset, France). Animals were
housed at the large animal facility of our laboratory and all
experiments were performed in accordance with our institutional
ethical guidelines. Pharmacokinetic studies of rhC1INH were
performed in naive animals. Three groups of transplant recipients
were included for study: three nonimmunized recipients receiving
no treatment, four immunized recipients receiving no treatment and
six immunized recipients receiving three daily i.v. injections of
rhC1INH for the first 5 posttransplant days. The first injection was
performed before declamping of graft vessels. Two of the six treated
animals received 100 U/kg of rhC1INH per injection and four others
received 200 U/kg per injection.
Immunization protocol
Donor-recipient pairs were chosen according to an identical blood
group, the absence of preformed DSAs, and major histocompat-
ibility complex (class II) mismatching assessed by positive mixed
lymphocyte culture and PCR techniques (data not shown). Briefly,
80 ml of heparinized blood were harvested from donors and PBMCs
were isolated by density gradient centrifugation. After lysis of red
blood cells, cells were resuspended in phosphate-buffered saline and
adjusted to 20 106 cells per ml to be injected intradermally into
recipients (two injections of 1 ml per animal). A challenge injection
was performed with the same protocol 2 weeks later. After
confirmation of immunization by FACS, each animal received a renal
transplant from the original donor at the plateau of immunization.
Anti-donor Ab detection
Donor PBMCs were incubated for 30 min at room temperature with
heat-inactivated recipient sera collected weekly. After washing in
FACS buffer, cells were incubated with fluorescein isothiocyanate-
labeled goat anti-monkey IgG (H&L, Serotec, Oxford, UK) for
30 min on ice in the dark. Cells were washed and resuspended in
FACS buffer and analyzed using a LSR II Flow cytometer (Becton
Dickinson, San Diego, CA, USA) with DIVA software (Becton
Dickinson). To assess the specificity of immunization, serum
samples were tested in parallel with autologous recipient and
third-party cells.
Complement-mediated cytotoxicity assay
As previously described,21 donor PBMCs were stained with
propidium iodide, after being incubated with recipient sera and
rabbit complement, to be analyzed by FACS. To assess cytotoxic
specificity, autologous and third-party cells were also tested. As
previously described,22 to determine whether immunized animals
developed anti-Class I alloAbs, positive recipient sera were incubated
twice for 1 h at room temperature with 10 109 donor platelets and
tested. In some experiments, the rabbit complement incubation step
was performed in the presence of different concentrations of
rhC1INH (0, 0.06, 0.12, 0.25, 0.5, 1, 2, and 3 g/l).
Renal transplantation
Life-sustaining renal allotransplantation was performed as pre-
viously described.22 The 24-h diuresis as well as blood urea nitrogen
were monitored daily. Transplantectomy was performed when
plasma creatinine increased to 400 mM and/or absence of diuresis.
Kidney graft biopsies were performed at day 3 posttransplantation
in some immunized recipients treated with 200 U/kg of rhC1INH
and surgical biopsies were performed in all animals before killing.
One biopsy fragment was collected for hematoxylin and eosin
histological examination and a second fragment was placed in Tissue
Tek O.C.T. Compound (Miles, Tarrytown, NY, USA), snap frozen
in liquid nitrogen, and stored at 80 1C for immunohistochemical
studies.
Histology and immunohistochemistry
Paraffin-embedded tissues were cut into 4 mm-thick sections and
stained with hematoxylin and eosin. All sections were examined by a
pathologist in a blinded manner.
Immunostainings were performed on transplantectomy
sections cut at a thickness of 10 mm and fixed in acetone. Sections
were incubated overnight at 4 1C with a rabbit anti-human CD3
(Dako, Glostrup, Denmark), mouse anti-human CD20 (clone L26,
Dako), mouse anti-human C4d (Quidel, San Diego, CA, USA),
mouse anti-human C5b-9 (clone aE11, Diatec, Oslo, Norway) or
rabbit anti-human C3c (Dako). After washing, sections were
incubated with either fluorescein isothiocyanate-labeled goat anti-
mouse IgG (Beckman Coulter, Fullerton, CA, USA) or fluorescein
isothiocyanate-labeled donkey anti-rabbit IgG (Jackson ImmunoRe-
search, West Grove, PA, USA) for 90 min at room temperature.
Sections were analyzed using a fluorescence microscope and Axion
Vision software (Carl Zeiss, Le Pecq, France). All Abs used for
staining were previously checked for crossreactivity on baboon
counterpart.
Measurement of serum total IgG and complement monitoring
Total IgG level was evaluated by serum electrophoresis. Complement
factors were measured in 1/20-diluted heparinized samples using
rabbit antisera to human complement factors C1-inhibitor, C3, and
C4 (Dade Behring, King of Prussia, PA, USA). Measurements were
made by a Berhing Analyzer II machine using nephelometry at room
temperature and after 4 h of incubation. Analysis of the classical
(CH50), alternative (AP50), and mannose-binding lectin (MBL50)
pathways of the complement system were determined by enzyme-
linked immunosorbent assay as previously described.26 Moreover, a
functional kinetic analysis of CH50 was also performed during the
first few hours after transplantation, as well as rhC1INH injection
on two immunized recipients treated with 200 U/kg of rhC1INH,
using a classical sheep erythrocyte assay dosing the released
hemoglobin.
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